Monte Rosa Therapeutics, Inc. (GLUE): Capital Expenditures
$4.70M
Year ended 2025-12-31
$8.01M
Trailing 12 months to 2026-06-30
-28.6%
3-year compound annual growth
+6.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.70M | +17.9% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $3.99M | -79.1% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $19.04M | +47.5% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $12.91M | +32.7% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $9.73M | +187.2% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $3.39M | n/a | 2022-03-29, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $0 | -100.0% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $14.95M | +67.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $7.67M | -87.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗